# A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).

> **NCT07005752** · PHASE4 · RECRUITING · sponsor: **Myungmoon Pharma. Co. Ltd.** · enrollment: 484 (estimated)

## Conditions studied

- Cholesterol Cholelithiasis

## Interventions

- **DRUG:** CnU cap. 250mg & Ursa placebo tab. 200mg
- **DRUG:** Ursa tab. 200mg & CnU placebo cap. 250mg

## Key facts

- **NCT ID:** NCT07005752
- **Lead sponsor:** Myungmoon Pharma. Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07005752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07005752, "A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07005752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*